InsiderSource
AGIO

AGIOS PHARMACEUTICALS, INC.

SEC CIK 1439222
$28.72 +2.8% · 90 days
90-day buys
$0
0 open-market
90-day sells
$1.2M
7 open-market
Net insider flow
−$1.2M
Net selling
Filings shown
77
Most recent

At a glance

Over the last 90 days, insiders at AGIO have sold a net $1.2M of stock (0 open-market buys vs 7 sells).

Largest recent trade: Goff Brian sold $432.9K of AGIO, trimming their stake 7%.

Most active filer: Gheuens Sarah, with 16 transactions among the recent filings shown.

Insider transaction history

Form 4 filings for AGIO, newest first
View on SEC EDGAR ↗
AGIO
AGIOS PHARMACEUTICALS, INC.
Sell Burns James William · Chief Legal Officer · Open-market sale · filed Apr 6, 2026 ΔOwn −6.2%

Burns James William sold $113.8K of AGIO, trimming their stake 6%.

−$113.8K
3,280 sh @ $35
AGIO
AGIOS PHARMACEUTICALS, INC.
Sell Gheuens Sarah · Chief Medical Officer · Open-market sale · filed Apr 6, 2026 ΔOwn −3.5%

Gheuens Sarah sold $102K of AGIO, trimming their stake 4%.

−$102K
2,940 sh @ $35
AGIO
AGIOS PHARMACEUTICALS, INC.
Sell Jones Cecilia · Chief Financial Officer · Open-market sale · filed Apr 6, 2026 ΔOwn −5.4%

Jones Cecilia sold $109K of AGIO, trimming their stake 5%.

−$109K
3,141 sh @ $35
AGIO
AGIOS PHARMACEUTICALS, INC.
Sell Milanova Tsveta · Chief Commercial Officer · Open-market sale · filed Apr 6, 2026 ΔOwn −6.5%

Milanova Tsveta sold $113.2K of AGIO, trimming their stake 7%.

−$113.2K
3,262 sh @ $35
AGIO
AGIOS PHARMACEUTICALS, INC.
Sell Viswanadhan Krishnan · Chief Corp Dev & Strategy · Open-market sale · filed Apr 6, 2026 ΔOwn −22%

Viswanadhan Krishnan sold $102.7K of AGIO, trimming their stake 22%.

−$102.7K
2,959 sh @ $35
AGIO
AGIOS PHARMACEUTICALS, INC.
Sell Goff Brian · Director, Chief Executive Officer · Open-market sale · filed Apr 6, 2026 ΔOwn −6.6%

Goff Brian sold $432.9K of AGIO, trimming their stake 7%.

−$432.9K
12,472 sh @ $35
AGIO
AGIOS PHARMACEUTICALS, INC.
Sell Goff Brian · Director, Chief Executive Officer · Open-market sale · filed Apr 6, 2026 ΔOwn −3.5%

Goff Brian sold $228.9K of AGIO, trimming their stake 3%.

−$228.9K
6,596 sh @ $35
AGIO
AGIOS PHARMACEUTICALS, INC.
Sell Viswanadhan Krishnan · Chief Corp Dev & Strategy · Open-market sale · filed Mar 9, 2026 ΔOwn −37%

Viswanadhan Krishnan sold $82.3K of AGIO, trimming their stake 37%.

−$82.3K
2,959 sh @ $28
AGIO
AGIOS PHARMACEUTICALS, INC.
Sell Goff Brian · Director, Chief Executive Officer · Open-market sale · filed Mar 3, 2026 ΔOwn −2.6%

Goff Brian sold $112.1K of AGIO, trimming their stake 3%.

−$112.1K
3,870 sh @ $29
AGIO
AGIOS PHARMACEUTICALS, INC.
Sell Goff Brian · Director, Chief Executive Officer · Open-market sale · filed Mar 3, 2026 ΔOwn −5.0%

Goff Brian sold $239.4K of AGIO, trimming their stake 5%.

−$239.4K
8,267 sh @ $29
AGIO
AGIOS PHARMACEUTICALS, INC.
Sell Goff Brian · Director, Chief Executive Officer · Open-market sale · filed Mar 3, 2026 ΔOwn −3.5%

Goff Brian sold $171.4K of AGIO, trimming their stake 3%.

−$171.4K
5,918 sh @ $29
AGIO
AGIOS PHARMACEUTICALS, INC.
Sell Gheuens Sarah · Chief Medical Officer · Open-market sale · filed Mar 3, 2026 ΔOwn −1.7%

Gheuens Sarah sold $34.4K of AGIO, trimming their stake 2%.

−$34.4K
1,187 sh @ $29
AGIO
AGIOS PHARMACEUTICALS, INC.
Sell Gheuens Sarah · Chief Medical Officer · Open-market sale · filed Mar 3, 2026 ΔOwn −2.3%

Gheuens Sarah sold $48.7K of AGIO, trimming their stake 2%.

−$48.7K
1,681 sh @ $29
AGIO
AGIOS PHARMACEUTICALS, INC.
Sell Gheuens Sarah · Chief Medical Officer · Open-market sale · filed Mar 3, 2026 ΔOwn −1.6%

Gheuens Sarah sold $34.4K of AGIO, trimming their stake 2%.

−$34.4K
1,187 sh @ $29
AGIO
AGIOS PHARMACEUTICALS, INC.
Sell Jones Cecilia · Chief Financial Officer · Open-market sale · filed Mar 3, 2026 ΔOwn −1.5%

Jones Cecilia sold $17.2K of AGIO, trimming their stake 2%.

−$17.2K
594 sh @ $29
AGIO
AGIOS PHARMACEUTICALS, INC.
Sell Jones Cecilia · Chief Financial Officer · Open-market sale · filed Mar 3, 2026 ΔOwn −3.8%

Jones Cecilia sold $48.7K of AGIO, trimming their stake 4%.

−$48.7K
1,681 sh @ $29
AGIO
AGIOS PHARMACEUTICALS, INC.
Sell Jones Cecilia · Chief Financial Officer · Open-market sale · filed Mar 3, 2026 ΔOwn −2.5%

Jones Cecilia sold $34.4K of AGIO, trimming their stake 3%.

−$34.4K
1,187 sh @ $29
AGIO
AGIOS PHARMACEUTICALS, INC.
Sell Jones Cecilia · Chief Financial Officer · Open-market sale · filed Mar 3, 2026 ΔOwn −3.1%

Jones Cecilia sold $45.6K of AGIO, trimming their stake 3%.

−$45.6K
1,573 sh @ $29
AGIO
AGIOS PHARMACEUTICALS, INC.
Sell Milanova Tsveta · Chief Commercial Officer · Open-market sale · filed Mar 3, 2026 ΔOwn −4.2%

Milanova Tsveta sold $48.7K of AGIO, trimming their stake 4%.

−$48.7K
1,681 sh @ $29
AGIO
AGIOS PHARMACEUTICALS, INC.
Sell Milanova Tsveta · Chief Commercial Officer · Open-market sale · filed Mar 3, 2026 ΔOwn −2.8%

Milanova Tsveta sold $34.4K of AGIO, trimming their stake 3%.

−$34.4K
1,187 sh @ $29
AGIO
AGIOS PHARMACEUTICALS, INC.
Sell Milanova Tsveta · Chief Commercial Officer · Open-market sale · filed Jan 7, 2026 ΔOwn −7.6%

Milanova Tsveta sold $77.6K of AGIO, trimming their stake 8%.

−$77.6K
2,872 sh @ $27
AGIO
AGIOS PHARMACEUTICALS, INC.
Sell Goff Brian · Director, Chief Executive Officer · Open-market sale · filed Jan 2, 2026 ΔOwn −8.4%

Goff Brian sold $337.9K of AGIO, trimming their stake 8%.

−$337.9K
12,473 sh @ $27
AGIO
AGIOS PHARMACEUTICALS, INC.
Sell Goff Brian · Director, Chief Executive Officer · Open-market sale · filed Jan 2, 2026 ΔOwn −4.2%

Goff Brian sold $168.8K of AGIO, trimming their stake 4%.

−$168.8K
6,230 sh @ $27
AGIO
AGIOS PHARMACEUTICALS, INC.
Sell Gheuens Sarah · Chief Medical Officer · Open-market sale · filed Jan 2, 2026 ΔOwn −4.3%

Gheuens Sarah sold $79.4K of AGIO, trimming their stake 4%.

−$79.4K
2,932 sh @ $27
AGIO
AGIOS PHARMACEUTICALS, INC.
Sell Milanova Tsveta · Chief Commercial Officer · Open-market sale · filed Jan 2, 2026 ΔOwn −9.1%

Milanova Tsveta sold $79.4K of AGIO, trimming their stake 9%.

−$79.4K
2,932 sh @ $27
AGIO
AGIOS PHARMACEUTICALS, INC.
Sell Jones Cecilia · Chief Financial Officer · Open-market sale · filed Jan 2, 2026 ΔOwn −7.3%

Jones Cecilia sold $79.4K of AGIO, trimming their stake 7%.

−$79.4K
2,932 sh @ $27
AGIO
AGIOS PHARMACEUTICALS, INC.
Sell Scadden David · Director · Open-market sale · filed Nov 14, 2025 ΔOwn −1.1%

Scadden David sold $8.8K of AGIO, trimming their stake 1%.

−$8.8K
200 sh @ $44
AGIO
AGIOS PHARMACEUTICALS, INC.
Sell Gheuens Sarah · Chief Medical Officer · Open-market sale · filed Nov 13, 2025 ΔOwn −3.8%

Gheuens Sarah sold $107.4K of AGIO, trimming their stake 4%.

−$107.4K
2,454 sh @ $44
AGIO
AGIOS PHARMACEUTICALS, INC.
Sell Gheuens Sarah · Chief Medical Officer · Open-market sale · filed Oct 29, 2025 ΔOwn −5.1%

Gheuens Sarah sold $145K of AGIO, trimming their stake 5%.

−$145K
3,302 sh @ $44

About AGIO insider activity

This page tracks every recent Form 4 filed for AGIOS PHARMACEUTICALS, INC. with the U.S. Securities and Exchange Commission. Form 4 is the disclosure that company insiders — officers, directors, and holders of more than 10% of the stock — must file within two business days of buying or selling shares.

The summary above nets open-market purchases against open-market sales over the trailing 90 days. Open-market trades (codes P and S) tend to carry the most signal because they reflect a deliberate choice to put money in or take it out, as opposed to routine grants, option exercises, or tax-withholding events. Use the badges on each row to tell them apart, and always confirm details against the original filing before drawing conclusions.

Frequently asked questions

How often is AGIO insider data updated?

Continuously. We read from SEC EDGAR, so new Form 4 filings for AGIOS PHARMACEUTICALS, INC. usually appear here within minutes of being accepted by the SEC.

What does "net insider flow" mean?

It is the total dollar value of open-market insider purchases minus open-market sales over the last 90 days. A positive number (green) means insiders bought more than they sold; a negative number (red) means the reverse.

Why do some rows show grants or option exercises instead of buys?

Insiders receive stock through compensation as well as buying it outright. Form 4 captures all of these. We label each transaction by its SEC code so you can focus on open-market activity if you prefer.

Is this investment advice?

No. InsiderSource presents public filing data for informational purposes only. Insider activity is one of many factors to consider and is never a recommendation to buy or sell.